PharmaCielo (PCLOF) News
Latest news and analysis
PharmaCielo Plummets 26.4% as CBD Stock Hits Multi-Month Lows
PharmaCielo shares crashed to $0.04 amid increased selling pressure, with the Colombian CBD company now trading near 52-week lows.
PharmaCielo Crashes 26.4% as CBD Company Hits New Lows
PharmaCielo plummeted to $0.04 per share amid continued struggles in the CBD market, trading near 52-week lows with elevated volume.
PharmaCielo Crashes 26.4% as CBD Stock Hits New Lows
PharmaCielo plummeted 26.4% to $0.04, bringing its market cap to just $7.4M as the CBD company continues its steep decline from 52-week highs.
PharmaCielo Crashes 26.4% as CBD Stock Hits Near 52-Week Low
PCLOF plummeted to $0.04 on elevated volume of 30,126 shares, bringing market cap down to $7.4M amid ongoing sector headwinds.
PharmaCielo Plummets 26.4% as CBD Stock Hits Critical Support
PharmaCielo shares crashed to $0.04 on elevated volume, marking a new low for the struggling CBD company.
PharmaCielo Plummets 26.4% as CBD Stock Hits Near 52-Week Low
PharmaCielo shares crashed to $0.04 amid heavy selling pressure, bringing the Colombian cannabis company's market cap to just $7.4 million.
PharmaCielo Crashes 26.4% to Four-Cent Territory on Heavy Volume
Cannabis company PharmaCielo plummeted over a quarter of its value in a single session, hitting new lows amid increased trading activity.
PharmaCielo Shares Crater 26.4% as Cannabis Stock Hits New Lows
PharmaCielo plummeted to $0.04 per share amid heavy selling pressure, bringing the Colombian cannabis company's market cap down to just $7.4 million.
PharmaCielo Crashes 26.4% as CBD Stock Hits Near 52-Week Lows
PharmaCielo shares plummeted to $0.04 amid elevated trading volume, bringing the company's market cap down to just $7.4 million.
PharmaCielo Crashes 26% as CBD Stock Hits New Lows
PharmaCielo shares plummeted 26.4% to $0.04, marking another significant decline for the struggling CBD company as volume surged.
PharmaCielo Crashes 26.4% to Near-Zero Levels on Heavy Volume
PCLOF shares plummeted to $0.04 as the Colombian cannabis company faces mounting financial pressures amid sector-wide challenges.